NCT03956641

Brief Summary

Adaptated Physical Activity (APA) during treatment of cancer is one of the actual global health recommendation because of the benefits observed in several parameters evaluated in many clinical studies. A best knowledge of the physical and medical characteristics of patients, including type of cancer and type of treatment, is primordial to optimize the patient care and the effectiveness of APA programs. Descriptive, explorative and prospective study of 3 different populations: One population with locally advanced or metastatic non-small cell lung cancer treated with multiple therapeutic lines. Two different populations of early cancer patients and treated with a platinum-based regimen for colon cancer and a taxane-based chemotherapy for breast cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 21, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

September 17, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 17, 2020

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

February 11, 2020

Status Verified

February 1, 2020

Enrollment Period

1 year

First QC Date

April 18, 2019

Last Update Submit

February 10, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • evolution of exercise tolerance

    To describe exercise tolerance, by a six-minute walk test, in patients treated for a cancer (of lung, breast or colon) after 8 weeks of treatment.

    change from baseline exercise tolerance at 12 weeks after the end of the treatment

Secondary Outcomes (12)

  • measurement of parameters reflecting the physical condition

    change from baseline physical condition at 12 weeks after the end of the treatment

  • measurement of parameters reflecting the physical condition

    change from baseline physical condition at 12 weeks after the end of the treatment

  • measurement of parameters reflecting the physical condition

    change from baseline physical condition at 12 weeks after the end of the treatment

  • measurement of parameters reflecting the physical condition

    change from baseline physical condition at 12 weeks after the end of the treatment

  • measurement of parameters reflecting the physical condition

    change from baseline physical condition at 12 weeks after the end of the treatment

  • +7 more secondary outcomes

Study Arms (1)

experimental: observational cohort

EXPERIMENTAL

Evaluation of the physical condition and the quality of life

Other: Adaptated Physical Activity

Interventions

Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)

experimental: observational cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Woman with breast cancer treated with adjuvant chemotherapy (taxane) or patient with colon cancer treated with adjuvant regimen (FOLFOX) or patient with locally advanced or metastatic lung cancer
  • Patient without contraindication to the study-specific assessments
  • Eastern Cooperative Oncology Group ≤ 2
  • Age ≥ 18 years old
  • Life expectancy \> 6 months
  • Able to speak, read and understand French
  • Written informed consent obtained from the patient
  • Registration in a national health care system

You may not qualify if:

  • Patient with psychiatric, neurologic or musculoskeletal disorders
  • Pregnant or breastfeeding women
  • Minor or protected adult

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Paul Strauss

Strasbourg, 67200, France

RECRUITING

Related Publications (1)

  • Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousiniere A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF. Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol. Front Oncol. 2020 Aug 7;10:1304. doi: 10.3389/fonc.2020.01304. eCollection 2020.

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Roland SCHOTT, Md

    Centre Paul Strauss

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2019

First Posted

May 21, 2019

Study Start

September 17, 2019

Primary Completion

September 17, 2020

Study Completion

June 1, 2021

Last Updated

February 11, 2020

Record last verified: 2020-02

Locations